State litigation guide · New York

Elmiron Vision Loss Lawsuit in New York

Time limits apply in New York. Find out if you still qualify.

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

People's Justice Research TeamUpdated June 25, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Statute of limitations — New York

New York CPLR § 214(5) provides a 3-year statute of limitations for personal injury claims including pharmaceutical product liability. The discovery rule applies — the limitations period runs from the date the plaintiff discovered or reasonably should have discovered the vision injury and its connection to Elmiron. New York does not have a general statute of repose for product liability claims.

3 years from discovery of Elmiron-related vision injury

Filing venue

Where to File in New York

Federal Elmiron cases from New York are transferred to the MDL in the District of New Jersey (MDL No. 2973). New York state court claims may proceed in New York County (Manhattan), Kings County (Brooklyn), or other New York Supreme Court venues. New York applies a Frye standard for expert admissibility, which can be more permissive than the federal Daubert standard. The 3-year statute of limitations and absence of a product liability statute of repose make New York particularly favorable for patients who used Elmiron for many years before the retinal toxicity link was publicized.

New York data

Exposure in New York

New York population — fourth-largest state with dense concentration of urology and ophthalmology specialists, particularly in the NYC metropolitan area

19.6 million

Source: U.S. Census Bureau 2024

New York's statute of limitations for pharmaceutical injury claims — one year longer than most states, providing additional time for Elmiron claimants to identify and pursue claims

3 years

Source: CPLR § 214(5)

Approximate rate of pigmentary maculopathy found in patients who used Elmiron for more than 15 years in published ophthalmology studies

25%

Source: JAMA Ophthalmology

Keep reading